3 Vaccine Stocks to Watch as Flu Season Approaches

Group 1: Novavax Update - The FDA has placed a clinical hold on Novavax's combination and standalone influenza shot [1] - Novavax's stock has dropped 17.7% to $10.36, nearing its lowest close since mid-May, although it remains up 115% in 2024 [2] Group 2: Moderna's Market Position - Moderna's shares are trading at $57.42, close to a four-year low of $55.70, reflecting a year-to-date decline of 42.2% [3] - The decline is attributed to a significant budget cut and lowered expectations for its RSV drug, with plans to regain market share by 2025 [3] Group 3: GSK Developments - GSK's stock is up 0.5% to $39.17 following the FDA's acceptance of its new drug application for urinary tract infections [4] - The company received FDA approval for its RSV vaccine in the summer, although the stock did not react significantly, and shares are 5.8% higher in 2024 [4]